Alterations of 5-hydroxymethylcytosine in human cancers

Cancers

Volumn 5, Issue 3, 2013, Pages 786-814

  Mariani, Christopher J ^a   Madzo, Jozef ^a   Moen, Erika L ^a   Yesilkanal, Ali ^a   Godley, Lucy A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

5 hydroxymethylcytosine; 5 methylcytosine; Cancer; DNA methylation; Epigenetics; Ten eleven translocation; TET

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; 5 METHYLCYTOSINE; BISULFITE; CELL PROTEIN; CYTOSINE; DNA; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; RESTRICTION ENDONUCLEASE; TEN ELEVEN TRANSLOCATION 1; UNCLASSIFIED DRUG;

ALKYLATION; CANCER GRADING; CARCINOGENESIS; DEMETHYLATION; DNA METHYLATION; DNA MODIFICATION; EMBRYONIC STEM CELL; ENZYME ACTIVITY; EXCISION REPAIR; FERTILIZATION; GENE MUTATION; GENE SILENCING; GLIOBLASTOMA; HEMATOLOGIC MALIGNANCY; HUMAN; HYDROXYMETHYLATION; IMMUNOPRECIPITATION; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; MALIGNANT NEOPLASTIC DISEASE; MASS SPECTROMETRY; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PROMOTER REGION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; THIN LAYER CHROMATOGRAPHY; TRANSCRIPTION REGULATION;

EID: 84879596861     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers5030786     Document Type: Review

References (143)

1. Jones, P.A. Functions of DNA methylation: Islands, start sites, gene bodies and beyond. Nat. Rev. Genet. 2012, 13, 484-492.
2. Penn, N.W.; Suwalski, R.; O'Riley, C.; Bojanowski, K.; Yura, R. The presence of 5-hydroxymethylcytosine in animal deoxyribonucleic acid. Biochem. J. 1972, 126, 781-790.
3. Bogdanović, O.; Veenstra, G.J.C. DNA methylation and methyl-CpG binding proteins: developmental requirements and function. Chromosoma 2009, 118, 549-565.
4. Ono, R.; Taki, T.; Taketani, T.; Taniwaki, M.; Kobayashi, H.; Hayashi, Y. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t (10; 11)(q22; q23). Cancer Res. 2002, 62, 4075-4080.
5. Lorsbach, R.B.; Moore, J.; Mathew, S.; Raimondi, S.C.; Mukatira, S.T.; Downing, J.R. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia 2003, 17, 637-641.
6. Tahiliani, M.; Koh, K.P.; Shen, Y.; Pastor, W.A.; Bandukwala, H.; Brudno, Y.; Agarwal, S.; Iyer, L.M.; Liu, D.R.; Aravind, L.; Rao, A. Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324, 930-935.
7. Kriaucionis, S.; Heintz, N. The Nuclear DNA Base 5-Hydroxymethylcytosine is present in purkinje neurons and the brain. Science 2009, 324, 929-930.
8. Ito, S.; Shen, L.; Dai, Q.; Wu, S.C.; Collins, L.B.; Swenberg, J.A.; He, C.; Zhang, Y. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 2011, 333, 1300-1303.
9. He, Y.F.; Li, B.Z.; Li, Z.; Liu, P.; Wang, Y.; Tang, Q.; Ding, J.; Jia, Y.; Chen, Z.; Li, L. et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 2011, 333, 1303-1307.
10. Pfaffeneder, T.; Hackner, B.; Truß, M.; Münzel, M.; Müller, M.; Deiml, C.A.; Hagemeier, C.; Carell, T. The discovery of 5-formylcytosine in embryonic stem cell DNA. Angew. Chem. Int. Ed. 2011, 50, 7008-7012.
11. Valinluck, V.; Sowers, L.C. Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. Cancer Res. 2007, 67, 946-950.
12. Rai, K.; Huggins, I.J.; James, S.R.; Karpf, A.R.; Jones, D.A.; Cairns, B.R. DNA demethylation in zebrafish involves the coupling of a deaminase, a glycosylase, and Gadd45. Cell 2008, 135, 1201-1212.
13. Cortellino, S.; Xu, J.; Sannai, M.; Moore, R.; Caretti, E.; Cigliano, A.; Le Coz, M.; Devarajan, K.; Wessels, A.; Soprano, D. et al. Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. Cell 2011, 146, 67-79.
14. Guo, J.U.; Su, Y.; Zhong, C.; Ming, G.-L.; Song, H. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 2011, 145, 423-434.
15. Rangam, G.; Schmitz, K.-M.; Cobb, A.J.A.; Petersen-Mahrt, S.K. AID enzymatic activity is inversely proportional to the size of cytosine C5 orbital cloud. PLoS One 2012, 7, e43279.
16. Nabel, C.S.; Jia, H.; Ye, Y.; Shen, L.; Goldschmidt, H.L.; Stivers, J.T.; Zhang, Y.; Kohli, R.M. AID/APOBEC deaminases disfavor modified cytosines implicated in DNA demethylation. Nat. Chem. Biol. 2012, 8, 751-758.
17. Maiti, A.; Drohat, A.C. Thymine DNA glycosylase can rapidly excise 5-formylcytosine and 5-carboxylcytosine: Potential implications for active demethylation of CpG sites. J. Biol. Chem. 2011, 286, 35334-35338.
18. Schiesser, S.; Hackner, B.; Pfaffeneder, T.; Müller, M.; Hagemeier, C.; Truß, M.; Carell, T. Mechanism and stem-cell activity of 5-carboxycytosine decarboxylation determined by isotope tracing. Angew. Chem. Int. Ed. 2012, 51, 6516-6520.
19. Smiley, J.A.; Kundracik, M.; Landfried, D.A.; Barnes, V.R., Sr.; Axhemi, A.A. Genes of the thymidine salvage pathway: Thymine-7-hydroxylase from a Rhodotorula glutinis cDNA library and iso-orotate decarboxylase from Neurospora crassa. Biochim. Biophys. Acta 2005, 1723, 256-264.
20. Branco, M.R.; Ficz, G.; Reik, W. Uncovering the role of 5-hydroxymethylcytosine in the epigenome. Nat. Rev. Genet. 2011, 13, 7-13.
21. Song, C.-X.; Yi, C.; He, C. Mapping recently identified nucleotide variants in the genome and transcriptome. Nat. Biotechnol. 2012, 30, 1107-1116.
22. Yildirim, O.; Li, R.; Hung, J.-H.; Chen, P.B.; Dong, X.; Ee, L.-S.; Weng, Z.; Rando, O.J.; Fazzio, T.G. Mbd3/NURD complex regulates expression of 5-hydroxymethylcytosine marked genes in embryonic stem cells. Cell 2011, 147, 1498-1510.
23. Frauer, C.; Hoffmann, T.; Bultmann, S.; Casa, V.; Cardoso, M.C.; Antes, I.; Leonhardt, H. Recognition of 5-hydroxymethylcytosine by the Uhrf1 SRA domain. PLoS One 2011, 6, e21306.
24. Mellén, M.; Ayata, P.; Dewell, S.; Kriaucionis, S.; Heintz, N. MeCP2 binds to 5hmC enriched within active genes and accessible chromatin in the nervous system. Cell 2012, 151, 1417-1430
25. Spruijt, C.G.; Gnerlich, F.; Smits, A.H.; Pfaffeneder, T.; Jansen, P.W.T.C.; Bauer, C.; Münzel, M.; Wagner, M.; Müller, M.; Khan, F. et al. Dynamic Readers for 5-(Hydroxy)Methylcytosine and Its Oxidized Derivatives. Cell 2013, 152, 1146-1159.
26. Jin, S.-G.; Kadam, S.; Pfeifer, G.P. Examination of the specificity of DNA methylation profiling techniques towards 5-methylcytosine and 5-hydroxymethylcytosine. Nucleic Acids Res. 2010, 38, e125.
27. Huang, Y.; Pastor, W.A.; Shen, Y.; Tahiliani, M.; Liu, D.R.; Rao, A. The Behaviour of 5-Hydroxymethylcytosine in Bisulfite Sequencing. PLoS One 2010, 5, e8888.
28. Hershey, A.D.; Dixon, J.; Chase, M. Nucleic acid economy in bacteria infected with bacteriophage T2. J. Gen. Physiol. 1953, 37, 1-23.
29. Wyatt, G.R.; Cohen, S.S. The bases of the nucleic acids of some bacterial and animal viruses: the occurrence of 5-hydroxymethylcytosine. Biochem. J. 1953, 55, 774-782.
30. Pastor, W.A.; Huang, Y.; Henderson, H.R.; Agarwal, S.; Rao, A. The GLIB technique for genome-wide mapping of 5-hydroxymethylcytosine. Nat. Protoc. 2012, 7, 1909-1917.
31. Harris, D.C. Chapter 23: Introduction to Analytical Separations. In Quantitative Chemical Analysis, 7th ed.; W.H. Freeman and Company: New York, NY, USA, 2007; pp. 01-528.
32. Münzel, M.; Globisch, D.; Brückl, T.; Wagner, M.; Welzmiller, V.; Michalakis, S.; Müller, M.; Biel, M.; Carell, T. Quantification of the sixth DNA base hydroxymethylcytosine in the brain. Angew. Chem. Int. Ed. 2010, 49, 5375-5377.
33. Song, L.; James, S.R.; Kazim, L.; Karpf, A.R. Specific method for the determination of genomic DNA methylation by liquid chromatography-electrospray ionization tandem mass spectrometry. Anal. Chem. 2005, 77, 504-510.
34. Kornberg, S.R.; Zimmerman, S.B.; Kornberg, A. Glucosylation of deoxyribonucleic acid by enzymes from bacteriophage-infected Escherichia coli. J. Biol. Chem. 1961, 236, 1487-1493.
35. Szwagierczak, A.; Bultmann, S.; Schmidt, C.S.; Spada, F.; Leonhardt, H. Sensitive enzymatic quantification of 5-hydroxymethylcytosine in genomic DNA. Nucleic Acids Res. 2010, 38, e181.
36. Terragni, J.; Bitinaite, J.; Zheng, Y.; Pradhan, S. Biochemical characterization of recombinant β-glucosyltransferase and analysis of global 5-hydroxymethylcytosine in unique genomes. Biochemistry 2012, 51, 1009-1019.
37. Xu, W.; Yang, H.; Liu, Y.; Yang, Y.; Wang, P.; Kim, S.-H.; Ito, S.; Yang, C.; Wang, P.; Xiao, M.-T. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19, 17-30.
38. Ko, M.; Huang, Y.; Jankowska, A.M.; Pape, U.J.; Tahiliani, M.; Bandukwala, H.S.; An, J.; Lamperti, E.D.; Koh, K.P.; Ganetzky, R. et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010, 2011, 839-843.
39. Song, C.-X.; Szulwach, K.E.; Fu, Y.; Dai, Q.; Yi, C.; Li, X.; Li, Y.; Chen, C.-H.; Zhang, W.; Jian, X. et al. Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat. Biotechnol. 2010, 29, 68-72.
40. Huang, Y.; Pastor, W.A.; Zepeda-Martínez, J.A.; Rao, A. The anti-CMS technique for genome-wide mapping of 5-hydroxymethylcytosine. Nat. Protoc. 2012, 7, 1897-1908.
41. Krueger, F.; Kreck, B.; Franke, A.; Andrews, S.R. DNA methylome analysis using short bisulfate sequencing data. Nat. Meth. 2012, 9, 145-151.
42. Lim, J.-Q.; Tennakoon, C.; Li, G.; Wong, E.; Ruan, Y.; Wei, C.-L.; Sung, W.-K. BatMeth: Improved mapper for bisulfite sequencing reads on DNA methylation. Genome Biol. 2012, 13, R82.
43. Chatterjee, A.; Stockwell, P.A.; Rodger, E.J.; Morison, I.M. Comparison of alignment software for genome-wide bisulphite sequence data. Nucleic Acids Res. 2012, 40, e79.
44. Waalwijk, C.; Flavell, R.A. MspI, an isoschizomer of hpaII which cleaves both unmethylated and methylated hpaII sites. Nucleic Acids Res. 1978, 5, 3231-3236.
45. Shen, C.K.; Maniatis, T. Tissue-specific DNA methylation in a cluster of rabbit beta-like globin genes. Proc. Natl. Acad. Sci. USA 1980, 77, 6634-6638.
46. Kinney, S.M.; Chin, H.G.; Vaisvila, R.; Bitinaite, J.; Zheng, Y.; Esteve, P.O.; Feng, S.; Stroud, H.; Jacobsen, S.E.; Pradhan, S. Tissue-specific distribution and dynamic changes of 5-hydroxymethylcytosine in mammalian genomes. J. Biol. Chem. 2011, 286, 24685-24693.
47. Wang, H.; Guan, S.; Quimby, A.; Cohen-Karni, D.; Pradhan, S.; Wilson, G.; Roberts, R.J.; Zhu, Z.; Zheng, Y. Comparative characterization of the PvuRts1I family of restriction enzymes and their application in mapping genomic 5-hydroxymethylcytosine. Nucleic Acids Res. 2011, 39, 9294-9305.
48. Sun, Z.; Jolyon, T.; Borgaro, J.G.; Liu, Y.; Yu, L.; Guan, S.; Wang, H.; Sun, D.; Cheng, X.; Zhu, Z. et al. High-Resolution Enzymatic Mapping of Genomic 5-Hydroxymethylcytosine in Mouse Embryonic Stem Cells. Cell Rep. 2013, 3, 567-576.
49. Booth, M.J.; Branco, M.R.; Ficz, G.; Oxley, D.; Krueger, F.; Reik, W.; Balasubramanian, S. Quantitative sequencing of 5-methylcytosine and 5-hydroxymethylcytosine at single-base resolution. Science 2012, 336, 934-937.
50. Yu, M.; Hon, G.C.; Szulwach, K.E.; Song, C.-X.; Zhang, L.; Kim, A.; Li, X.; Dai, Q.; Shen, Y.; Park, B. et al. Base-Resolution Analysis of 5-Hydroxymethylcytosine in the Mammalian Genome. Cell 2012, 149, 1368-1380.
51. Flusberg, B.A.; Webster, D.R.; Lee, J.H.; Travers, K.J.; Olivares, E.C.; Clark, T.A.; Korlach, J.; Turner, S.W. Direct detection of DNA methylation during single-molecule, real-time sequencing. Nat. Meth. 2010, 7, 461-465.
52. Song, C.-X.; Clark, T.A.; Lu, X.-Y.; Kislyuk, A.; Dai, Q.; Turner, S.W.; He, C.; Korlach, J. Sensitive and specific single-molecule sequencing of 5-hydroxymethylcytosine. Nat. Meth. 2011, 9, 75-77.
53. Oswald, J.; Engemann, S.; Lane, N.; Mayer, W.; Olek, A.; Fundele, R.; Dean, W.; Reik, W.; Walter, J. Active demethylation of the paternal genome in the mouse zygote. Curr. Biol. 2000, 10, 475-478.
54. Mayer, W.; Niveleau, A.; Walter, J.; Fundele, R.; Haaf, T. Embryogenesis: demethylation of the zygotic paternal genome. Nature 2000, 403, 501-502.
55. Wossidlo, M.; Nakamura, T.; Lepikhov, K.; Marques, C.J.; Zakhartchenko, V.; Boiani, M.; Arand, J.; Nakano, T.; Reik, W.; Walter, J.O.R. 5-Hydroxymethylcytosine in the mammalian zygote is linked with epigenetic reprogramming. Nat. Commun. 2011, 2, 241-248
56. Iqbal, K.; Jin, S.G.; Pfeifer, G.P.; Szabó, P.E. Reprogramming of the paternal genome upon fertilization involves genome-wide oxidation of 5-methylcytosine. Proc. Natl. Acad. Sci. USA 2011, 108, 3642-3647.
57. Inoue, A.; Zhang, Y. Replication-dependent loss of 5-hydroxymethylcytosine in mouse preimplantation embryos. Science 2011, 334, 194.
58. Gu, T.-P.; Guo, F.; Yang, H.; Wu, H.-P.; Xu, G.-F.; Liu, W.; Xie, Z.-G.; Shi, L.; He, X.; Jin, S.-G. et al. The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes. Nature 2011, 477, 606-610.
59. Li, G.; Reinberg, D. Chromatin higher-order structures and gene regulation. Curr. Opin. Genet. Dev. 2011, 21, 175-186.
60. Nakamura, T.; Liu, Y.-J.; Nakashima, H.; Umehara, H.; Inoue, K.; Matoba, S.; Tachibana, M.; Ogura, A.; Shinkai, Y.; Nakano, T. PGC7 binds histone H3K9me2 to protect against conversion of 5mC to 5hmC in early embryos. Nature 2012, 486, 415-419.
61. Koh, K.P.; Yabuuchi, A.; Rao, S.; Huang, Y.; Cunniff, K.; Nardone, J.; Laiho, A.; Tahiliani, M.; Sommer, C.A.; Mostoslavsky, G. et al. Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. Cell Stem Cell 2011, 8, 200-213.
62. Ficz, G.; Branco, M.R.; Seisenberger, S.; Santos, F.; Krueger, F.; Hore, T.A.; Marques, C.J.; Andrews, S.; Reik, W. Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. Nature 2011, 473, 398-402.
63. Ito, S.; D'Alessio, A.C.; Taranova, O.V.; Hong, K.; Sowers, L.C.; Zhang, Y. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010, 466, 1129-1133.
64. Costa, Y.; Ding, J.; Theunissen, T.W.; Faiola, F.; Hore, T.A.; Shliaha, P.V.; Fidalgo, M.; Saunders, A.; Lawrence, M.; Dietmann, S. et al. NANOG-dependent function of TET1 and TET2 in establishment of pluripotency. Nature 2013, 495, 370-374.
65. Dawlaty, M.M.; Ganz, K.; Powell, B.E.; Hu, Y.-C.; Markoulaki, S.; Cheng, A.W.; Gao, Q.; Kim, J.; Choi, S.-W.; Page, D.C. et al. Tet1 Is dispensable for maintaining pluripotency and its loss Is compatible with embryonic and postnatal development. Cell Stem Cell 2011, 9, 166-175.
66. Dawlaty, M.M.; Breiling, A.; Le, T.; Raddatz, G.; Barrasa, M.I.; Cheng, A.W.; Gao, Q.; Powell, B.E.; Li, Z.; Xu, M. et al. Combined deficiency of Tet1 and Tet2 causes epigenetic abnormalities but is compatible with postnatal development. Dev. Cell 2013, 3, 310-323.
67. Xu, Y.; Wu, F.; Tan, L.; Kong, L.; Xiong, L.; Deng, J.; Barbera, A.J.; Zheng, L.; Zhang, H.; Huang, S. et al. Genome-wide regulation of 5hmC, 5mC, and gene expression by Tet1 hydroxylase in mouse embryonic stem cells. Mol. Cell 2011, 42, 451-464.
68. Wu, H.; D'Alessio, A.C.; Ito, S.; Xia, K.; Wang, Z.; Cui, K.; Zhao, K.; Sun, Y.E.; Zhang, Y. Dual functions of Tet1 in transcriptional regulation in mouse embryonic stem cells. Nature 2011, 473, 389-393.
69. Globisch, D.; Münzel, M.; Müller, M.; Michalakis, S.; Wagner, M.; Koch, S.; Brückl, T.; Biel, M.; Carell, T. Tissue Distribution of 5-Hydroxymethylcytosine and Search for Active Demethylation Intermediates. PLoS One 2010, 5, e15367.
70. Szulwach, K.E.; Li, X.; Li, Y.; Song, C.-X.; Wu, H.; Dai, Q.; Irier, H.; Upadhyay, A.K.; Gearing, M.; Levey, A.I. et al. 5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. Nat. Neurosci. 2011, 14, 1607-1616.
71. Khare, T.; Pai, S.; Koncevicius, K.; Pal, M.; Kriukiene, E.; Liutkeviciute, Z.; Irimia, M.; Jia, P.; Ptak, C.; Xia, M. et al. 5-hmC in the brain is abundant in synaptic genes and shows differences at the exon-intron boundary. Nat. Struct. Mol. Biol. 2012, 19, 1037-1043.
72. Louis, D.N.; Ohgaki, H.; Wiestler, O.D.; Cavenee, W.K.; Burger, P.C.; Jouvet, A.; Scheithauer, B.W.; Kleihues, P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114, 97-109.
73. Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352, 987-996.
74. Fanelli, M.; Caprodossi, S.; Ricci-Vitiani, L.; Porcellini, A.; Tomassoni-Ardori, F.; Amatori, S.; Andreoni, F.; Magnani, M.; de Maria, R.; Santoni, A. et al. Loss of pericentromeric DNA methylation pattern in human glioblastoma is associated with altered DNA methyltransferases expression and involves the stem cell compartment. Oncogene 2007, 27, 358-365.
75. Cadieux, B.; Ching, T.-T.; VandenBerg, S.R.; Costello, J.F. Genome-wide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate reductase allele status, and increased proliferation. Cancer Res. 2006, 66, 8469-8476.
76. Orr, B.A.; Haffner, M.C.; Nelson, W.G.; Yegnasubramanian, S.; Eberhart, C.G. Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma. PLoS One 2012, 7, e41036.
77. Kraus, T.F.J.; Globisch, D.; Wagner, M.; Eigenbrod, S.; Widmann, D.; Münzel, M.; Müller, M.; Pfaffeneder, T.; Hackner, B.; Feiden, W. et al. Low values of 5-hydroxymethylcytosine (5hmC), the "sixth base," are associated with anaplasia in human brain tumors. Int. J. Cancer 2012, 131, 1577-1590.
78. Reitman, Z.J.; Yan, H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J. Natl. Cancer Inst. 2010, 102, 932-941.
79. Balss, J.; Meyer, J.; Mueller, W.; Korshunov, A.; Hartmann, C.; Deimling, A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008, 116, 597-602.
80. Noushmehr, H.; Weisenberger, D.J.; Diefes, K.; Phillips, H.S.; Pujara, K.; Berman, B.P.; Pan, F.; Pelloski, C.E.; Sulman, E.P.; Bhat, K.P. et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010, 17, 510-522.
81. Parsons, D.W.; Jones, S.; Zhang, X.; Lin, J.C.-H.; Leary, R.J.; Angenendt, P.; Mankoo, P.; Carter, H.; Siu, I.-M.; Gallia, G.L. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321, 1807-1812.
82. Christensen, B.C.; Smith, A.A.; Zheng, S.; Koestler, D.C.; Houseman, E.A.; Marsit, C.J.; Wiemels, J.L.; Nelson, H.H.; Karagas, M.R.; Wrensch, M.R. et al. DNA Methylation, Isocitrate Dehydrogenase Mutation, and Survival in Glioma. J. Natl. Cancer Inst. 2011, 103, 143-153.
83. Turcan, S.; Rohle, D.; Goenka, A.; Walsh, L.A.; Fang, F.; Yilmaz, E.; Campos, C.; Fabius, A.W.M.; Lu, C.; Ward, P.S. et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012, 483, 479-483.
84. Figueroa, M.E.; Abdel-Wahab, O.; Lu, C.; Ward, P.S.; Patel, J.; Shih, A.; Li, Y.; Bhagwat, N.; Vasanthakumar, A.; Fernandez, H.F. et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18, 553-567.
85. Müller, T.; Gessi, M.; Waha, A.; Isselstein, L.J.; Luxen, D.; Freihoff, D.; Freihoff, J.; Becker, A.; Simon, M.; Hammes, J. et al. Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas. Am. J. Pathol. 2012, 181, 675-683.
86. Liu, Y.; Jiang, W.; Liu, J.; Zhao, S.; Xiong, J.; Mao, Y.; Wang, Y. IDH1 mutations inhibit multiple α-ketoglutarate-dependent dioxygenase activities in astroglioma. J. Neurooncol. 2012, 109, 253-260.
87. Kim, Y.H.; Pierscianek, D.; Mittelbronn, M.; Vital, A.; Mariani, L.; Hasselblatt, M.; Ohgaki, H. TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations. J. Clin. Pathol. 2011, 64, 850-852.
88. Verhaak, R.G.W.; Hoadley, K.A.; Purdom, E.; Wang, V.; Qi, Y.; Wilkerson, M.D.; Miller, C.R.; Ding, L.; Golub, T.; Mesirov, J.P. et al. Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17, 98-110.
89. McLendon, R.; Friedman, A.; Bigner, D.; van Meir, E.G.; Brat, D.J.; M Mastrogianakis, G.; Olson, J.J.; Mikkelsen, T.; Lehman, N. et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455, 1061-1068.
90. Ko, M.; Bandukwala, H.S.; An, J.; Lamperti, E.D.; Thompson, E.C.; Hastie, R.; Tsangaratou, A.; Rajewsky, K.; Koralov, S.B.; Rao, A. Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc. Natl. Acad. Sci. USA 2011, 108, 14566-14571.
91. Moran-Crusio, K.; Reavie, L.; Shih, A.; Abdel-Wahab, O.; Ndiaye-Lobry, D.; Lobry, C.; Figueroa, M.E.; Vasanthakumar, A.; Patel, J.; Zhao, X. et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011, 20, 11-24.
92. Sasaki, M.; Knobbe, C.B.; Munger, J.C.; Lind, E.F.; Brenner, D.; Brüstle, A.; Harris, I.S.; Holmes, R.; Wakeham, A.; Haight, J. et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 2012, 488, 656-659.
93. Delhommeau, F.; Dupont, S.; Della Valle, V.; James, C.; Trannoy, S.; Massé, A.; Kosmider, O.; le Couedic, J.-P.; Robert, F.; Alberdi, A. et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 2009, 360, 2289-2301.
94. Langemeijer, S.M.C.; Kuiper, R.P.; Berends, M.; Knops, R.; Aslanyan, M.G.; Massop, M.; Stevens-Linders, E.; van Hoogen, P.; van Kessel, A.G.; Raymakers, R.A.P. et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat. Genet. 2009, 41, 838-842.
95. Abdel-Wahab, O.; Mullally, A.; Hedvat, C.; Garcia-Manero, G.; Patel, J.; Wadleigh, M.; Malinge, S.; Yao, J.; Kilpivaara, O.; Bhat, R. et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009, 114, 144-147.
96. Beer, P.A.; Delhommeau, F.; LeCouedic, J.P.; Dawson, M.A.; Chen, E.; Bareford, D.; Kusec, R.; McMullin, M.F.; Harrison, C.N.; Vannucchi, A.M. et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 2010, 115, 2891-2900.
97. Colaizzo, D.; Tiscia, G.L.; Pisanelli, D.; Bafunno, V.; Amitrano, L.; Grandone, E.; Guardascione, M.A.; Margaglione, M. New TET2 gene mutations in patients with myeloproliferative neoplasms and splanchnic vein thrombosis. J. Thromb. Haemost. 2010, 5, 1142-1144.
98. Couronné, L.; Lippert, E.; Andrieux, J.; Kosmider, O.; Radford-Weiss, I.; Penther, D.; Dastugue, N.; Mugneret, F.; Lafage, M.; Gachard, N. et al. Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias. Leukemia 2010, 24, 201-203.
99. Flach, J.; Dicker, F.; Schnittger, S.; Kohlmann, A.; Haferlach, T.; Haferlach, C. Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis. Haematologica 2010, 95, 518-519.
100. Gelsi-Boyer, V.; Trouplin, V.; Adélaïde, J.; Bonansea, J.; Cervera, N.; Carbuccia, N.; Lagarde, A.; Prebet, T.; Nezri, M.; Sainty, D. et al. Mutations of polycomb-associated gene ASXL1in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br. J. Haematol. 2009, 145, 788-800.
101. Jankowska, A.M.; Szpurka, H.; Tiu, R.V.; Makishima, H.; Afable, M.; Huh, J.; O'Keefe, C.L.; Ganetzky, R.; McDevitt, M.A.; Maciejewski, J.P. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 2009, 113, 6403-6410.
102. Kosmider, O.; Gelsi-Boyer, V.; Ciudad, M.; Racoeur, C.; Jooste, V.; Vey, N.; Quesnel, B.; Fenaux, P.; Bastie, J.N.; Beyne-Rauzy, O. et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica 2009, 94, 1676-1681.
103. Mohamedali, A.M.; Smith, A.E.; Gaken, J.; Lea, N.C.; Mian, S.A.; Westwood, N.B.; Strupp, C.; Gattermann, N.; Germing, U.; Mufti, G.J. Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. J. Clin. Orthod. 2009, 27, 4002-4006.
104. Nibourel, O.; Kosmider, O.; Cheok, M.; Boissel, N.; Renneville, A.; Philippe, N.; Dombret, H.; Dreyfus, F.; Quesnel, B.; Geffroy, S. et al. Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood 2010, 116, 1132-1135.
105. Schaub, F.X.; Looser, R.; Li, S.; Hao-Shen, H.; Lehmann, T.; Tichelli, A.; Skoda, R.C. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood 2010, 115, 2003-2007.
106. Szpurka, H.; Jankowska, A.M.; Makishima, H.; Bodo, J.; Bejanyan, N.; Hsi, E.D.; Sekeres, M.A.; Maciejewski, J.P. Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations. Leuk. Res. 2010, 34, 969-973.
107. Yamazaki, J.; Taby, R.; Vasanthakumar, A.; Macrae, T.; Ostler, K.R.; Shen, L.; Kantarjian, H.M.; Estecio, M.R.; Jelinek, J.; Godley, L.A. et al. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics 2012, 7, 201-207.
108. Quivoron, C.; Couronné, L.; Valle, D.V.; Lopez, C.K.; Plo, I.; Wagner-Ballon, O.; do Cruzeiro, M.; Delhommeau, F.; Arnulf, B. et al. TET2 Inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011, 20, 25-38.
109. Kunimoto, H.; Fukuchi, Y.; Sakurai, M.; Sadahira, K.; Ikeda, Y.; Okamoto, S.; Nakajima, H. Tet2 disruption leads to enhanced self-renewal and altered differentiation of fetal liver hematopoietic stem cells. Sci. Rep. 2012, 2, 273.
110. Li, Z.; Cai, X.; Cai, C.L.; Wang, J.; Zhang, W.; Petersen, B.E.; Yang, F.C.; Xu, M. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 2011, 118, 4509-4518.
111. Pronier, E.; Almire, C.; Mokrani, H.; Vasanthakumar, A.; Simon, A.; da Costa, R.M.B.; Masse, A.; Le Couedic, J.P.; Pendino, F.; Carbonne, B. et al. Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood 2011, 118, 2551-2555
112. Abdel-Wahab, O.; Manshouri, T.; Patel, J.; Harris, K.; Yao, J.; Hedvat, C.; Heguy, A.; Bueso-Ramos, C.; Kantarjian, H.; Levine, R.L. et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res. 2010, 70, 447-452.
113. Metzeler, K.H.; Maharry, K.; Radmacher, M.D.; Mrozek, K.; Margeson, D.; Becker, H.; Curfman, J.; Holland, K.B.; Schwind, S.; Whitman, S.P. et al. TET2 mutations improve the new european leukemianet risk classification of acute myeloid leukemia: A cancer and leukemia group B study. J. Clin. Orhtop. 2011, 29, 1373-1381.
114. Bejar, R.; Stevenson, K.; Abdel-Wahab, O.; Galili, N.; Nilsson, B.; Garcia-Manero, G.; Kantarjian, H.; Raza, A.; Levine, R.L.; Neuberg, D. Clinical effect of point mutations in myelodysplastic syndromes. N. Engl. J. Med. 2011, 364, 2496-2506.
115. Liu, X.; Guangsen, Z.; Yi, Y.; Xiao, L.; Pei, M.; Liu, S.; Luo, Y.; Zhong, H.; Xu, Y.; Zheng, W.; Shen, J. Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes. Leuk. Lymphoma 2013, doi:10.3109/ 10428194.2013.778408.
116. Sjoblom, T.; Jones, S.; Wood, L.D.; Parsons, D.W.; Lin, J.; Barber, T.D.; Mandelker, D.; Leary, R.J.; Ptak, J.; Silliman, N.; Szabo, S. et al. The Consensus Coding Sequences of Human Breast and Colorectal Cancers. Science 2006, 314, 268-274.
117. Yan, H.; Parsons, D.W.; Jin, G.; McLendon, R.; Rasheed, B.A.; Yuan, W.; Kos, I.; Batinic-Haberle, I.; Jones, S.; Riggins, G.J. et al. IDH1 and IDH2 mutations in gliomas. N. Engl.J. Med. 2009, 360, 765-773.
118. Patel, J.P.; Gonen, M.; Figueroa, M.E.; Fernandez, H.; Sun, Z.; Racevskis, J.; van Vlierberghe, P.; Dolgalev, I.; Thomas, S.; Aminova, O. et al. Prognostic relevance of integrated genetic profiling in acute myeloid Leukemia. N. Engl. J. Med. 2012, 366, 1079-1089.
119. Dang, L.; White, D.W.; Gross, S.; Bennett, B.D.; Bittinger, M.A.; Driggers, E.M.; Fantin, V.R.; Jang, H.G.; Jin, S.; Keenan, M.C. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462, 739-744.
120. Gross, S.; Cairns, R.A.; Minden, M.D.; Driggers, E.M.; Bittinger, M.A.; Jang, H.G.; Sasaki, M.; Jin, S.; Schenkein, D.P.; Su, S.M. et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J. Exp. Med. 2010, 207, 339-344.
121. Lu, C.; Ward, P.S.; Kapoor, G.S.; Rohle, D.; Turcan, S.; Abdel-Wahab, O.; Edwards, C.R.; Khanin, R.; Figueroa, M.E.; Melnick, A. et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012, 483, 474-478.
122. Chowdhury, R.; Yeoh, K.K.; Tian, Y.-M.; Hillringhaus, L.; Bagg, E.A.; Rose, N.R.; Leung, I.K.H.; Li, X.S.; Woon, E.C.Y.; Yang, M. et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 2011, 12, 463-469.
123. Koivunen, P.; Lee, S.; Duncan, C.G.; Lopez, G.; Lu, G.; Ramkissoon, S.; Losman, J.A.; Joensuu, P.; Bergmann, U.; Gross, S. et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 2012, 483, 484-488.
124. Losman, J.-A.; Looper, R.; Koivunen, P.; Lee, S.; Schneider, R.K.; McMahon, C.; Cowley, G.; Root, D.; Ebert, B.L.; Kaelin, W.G. (R)-2-Hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 2013, 339, 1621-1625.
125. Pollyea, D.A.; Kohrt, H.E.; Zhang, B.; Zehnder, J.; Schenkein, D.; Fantin, V.; Straley, K.; Vasanthakumar, A.; Abdel-Wahab, O.; Levine, R. et al. 2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels. Leuk. Lymphoma 2013, 54, 408-410.
126. Popovici-Muller, J.; Saunders, J.O.; Salituro, F.G.; Travins, J.M.; Yan, S.; Zhao, F.; Gross, S.; Dang, L.; Yen, K.E.; Yang, H. et al. Discovery of the first potent inhibitors of mutant IDH1 that lower tumor 2-HG in vivo. ACS Med. Chem. Lett. 2012, 3, 850-855.
127. Ward, P.S.; Patel, J.; Wise, D.R.; Abdel-Wahab, O.; Bennett, B.D.; Coller, H.A.; Cross, J.R.; Fantin, V.R.; Hedvat, C.V.; Perl, A.E. et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010, 17, 225-234.
128. Green, C.L.; Evans, C.M.; Hills, R.K.; Burnett, A.K.; Linch, D.C.; Gale, R.E. The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood 2010, 116, 2779-2782.
129. Green, C.L.; Evans, C.M.; Zhao, L.; Hills, R.K.; Burnett, A.K.; Linch, D.C.; Gale, R.E. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood 2011, 118, 409-412.
130. Döhner, K.; Schlenk, R.F.; Habdank, M.; Scholl, C.; Rücker, F.G.; Corbacioglu, A.; Bullinger, L.; Fröhling, S.; Döhner, H. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005, 106, 3740-3746.
131. Chotirat, S.; Thongnoppakhun, W.; Promsuwicha, O.; Boonthimat, C.; Auewarakul, C.U. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients. J. Hematol. Oncol. 2012, 5, 5.
132. Marcucci, G.; Maharry, K.; Wu, Y.Z.; Radmacher, M.D.; Mrozek, K.; Margeson, D.; Holland, K.B.; Whitman, S.P.; Becker, H.; Schwind, S. et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: A cancer and leukemia group B study. J. Clin. Orthod. 2010, 28, 2348-2355.
133. Paschka, P.; Schlenk, R.F.; Gaidzik, V.I.; Habdank, M.; Kronke, J.; Bullinger, L.; Spath, D.; Kayser, S.; Zucknick, M.; Gotze, K. et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J. Clin. Orhtod. 2010, 28, 3636-3643.
134. Vannucchi, A.M.; Lasho, T.L.; Guglielmelli, P.; Biamonte, F.; Pardanani, A.; Pereira, A.; Finke, C.; Score, J.; Gangat, N.; Mannarelli, C. et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013, 1-33.
135. Haffner, M.C.; Chaux, A.; Meeker, A.K.; Esopi, D.M.; Gerber, J.; Pellakuru, L.G.; Toubaji, A.; Argani, P.; Iacobuzio-Donahue, C.; Nelson, W.G. et al. Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget 2011, 2, 627-637.
136. Jin, S.G.; Jiang, Y.; Qiu, R.; Rauch, T.A.; Wang, Y.; Schackert, G.; Krex, D.; Lu, Q.; Pfeifer, G.P. 5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. Cancer Res. 2011, 71, 7360-7365.
137. Yang, H.; Liu, Y.; Bai, F.; Zhang, J.-Y.; Ma, S.-H.; Liu, J.; Xu, Z.-D.; Zhu, H.-G.; Ling, Z.-Q.; Ye, D. et al. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene 2013, 32, 663-669.
138. Chen, M.L.; Shen, F.; Huang, W.; Qi, J.H.; Wang, Y.; Feng, Y.Q.; Liu, S.M.; Yuan, B.F. Quantification of 5-methylcytosine and 5-hydroxymethylcytosine in genomic DNA from hepatocellular carcinoma tissues by capillary hydrophilic-Interaction liquid chromatography/ quadrupole TOF mass spectrometry. Clin. Chem. 2013, 59, 824-832.
139. Kudo, Y.; Tateishi, K.; Yamamoto, K.; Yamamoto, S.; Asaoka, Y.; Ijichi, H.; Nagae, G.; Yoshida, H.; Aburatani, H.; Koike, K. Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer Sci. 2012, 103, 670-676.
140. Lian, C.G.; Xu, Y.; Ceol, C.; Wu, F.; Larson, A.; Dresser, K.; Xu, W.; Tan, L.; Hu, Y.; Zhan, Q. et al. Loss of 5-Hydroxymethylcytosine Is an Epigenetic Hallmark of Melanoma. Cell 2012, 150, 1135-1146.
141. Gambichler, T.; Sand, M.; Skrygan, M. Loss of 5-hydroxymethylcytosine and ten-eleven translocation 2 protein expression in malignant melanoma. Melanoma Res. 2013, 23, 218-220.
142. Shibata, T.; Kokubu, A.; Miyamoto, M.; Sasajima, Y.; Yamazaki, N. Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation. Am. J. Pathol. 2011, 178, 1395-1402.
143. Hsu, C.-H.; Peng, K.-L.; Kang, M.-L.; Chen, Y.-R.; Yang, Y.-C.; Tsai, C.-H.; Chu, C.-S.; Jeng, Y.-M.; Chen, Y.-T.; Lin, F.-M. et al. TET1 suppresses cancer invasion by activating the tissue Inhibitors of metalloproteinases. Cell Rep. 2012, 2, 568-579.